Loading
Radiotherapy may make immunotherapy work better, but the trials to test this are scattered and often small. One shared platform, run by radiotherapy groups with drugs supplied by several companies, would settle it faster.
A master protocol operated by academic radiotherapy groups (through a neutral sponsor) in which multiple companies' immunotherapies are tested in combination with standardised radiotherapy schedules, doses and target volumes across defined indications (oligometastatic disease, locally advanced head and neck, lung, bladder), with a shared control arm and pre-specified translational sampling. Existing RT-IO trials use inconsistent radiotherapy, making negative and positive results hard to interpret. Radiotherapy groups have the trial infrastructure but no access to drugs; companies have drugs but do not prioritise radiotherapy combinations, so the pairing is a natural public-private platform.
Shares Global cancer surgery: delivering safe, affordable, and timely cancer surgery, Core-funded radiotherapy trials infrastructure with central quality assurance, Surgery and radiotherapy cure most, get least, SBRT / SABR (stereotactic radiotherapy).
Shares Radiotherapy + immunotherapy, Abscopal effect, Surgery and radiotherapy cure most, get least, SBRT / SABR (stereotactic radiotherapy).
Shares A permanent neutral non-profit sponsor for multi-company platform trials, Radiotherapy + immunotherapy, Secrecy and intellectual property block collaboration, Too many combinations to test.
Shares Abscopal effect, SBRT / SABR (stereotactic radiotherapy), IMRT / IGRT (modern external beam), Immune checkpoint inhibitors.
Shares Global cancer surgery: delivering safe, affordable, and timely cancer surgery, Core-funded radiotherapy trials infrastructure with central quality assurance, Surgery and radiotherapy cure most, get least, IMRT / IGRT (modern external beam).
Shares Abscopal effect, SBRT / SABR (stereotactic radiotherapy), IMRT / IGRT (modern external beam), Immune checkpoint inhibitors.
Shares Core-funded radiotherapy trials infrastructure with central quality assurance, Surgery and radiotherapy cure most, get least, SBRT / SABR (stereotactic radiotherapy), IMRT / IGRT (modern external beam).
Shares Too many combinations to test, Nivolumab, Pembrolizumab, Immune checkpoint inhibitors.